Fixed-combination travoprost 0.004%/timolol 0.5% for open-angle glaucoma or ocular hypertension

Expert Review of Ophthalmology

Volumn 1, Issue 1, 2006, Pages 25-30

  Kahook, Malik Y ^a   Awadallah, Nida S ^b   Noecker, Robert J ^c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^c University of Pittsburgh School of Medicine   (United States)

Author keywords

DuoTrav ; ocular hypertension; open angle glaucoma; timolol; travoprost

Indexed keywords

EID: 46449119650     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.1.1.25     Document Type: Article

References (25)

1. Goldberg I. Relationship between intraocular pressure and preservation of visual field in glaucoma. Surv. Ophthalmol. 48 (Suppl. 1), S3 –S7 (2003).
2. Kass MA, Heuer DK, Higginbotham EJ et al. The Ocular Hypertension Treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary-open angle glaucoma. Arch. Ophthalmol. 120, 701–713 (2002).
3. Lichter PR, Musch DC, Gillespie BW et al. CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment study comparing initial treatment randomized to medications or surgery. Ophthalmology 108, 1943–1953 (2001).
4. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am. J. Ophthalmol. 126, 487–497 (1998).
5. Patel SC, Spaeth GL. Compliance in patients prescribed eye drops for glaucoma. Ophthalmic Surg. 26, 233–236 (1995).
6. Weinreb RN. Compliance with medical treatment of glaucoma. J. Glaucoma 1, 134–136 (1992).
7. Chrai SS, Makoid MC, Eriksen SP, Robinson JR. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J. Pharm. Sci. 63, 333–338 (1974).
8. Sharir M, Zimmerman TJ, del Negro RG, Ball SF, Kooner KS. A comparison of the efficacy of various metipranolol–pilocarpine combinations in patients with ocular hypertension and primary open-angle glaucoma. J. Ocul. Pharmacol. 10, 411–420 (1994).
9. Moriarty AP, Dowd TC, Trimble RB. Clinical experience with a fixed dose combination therapy of timolol and pilocarpine used twice daily in the management of chronic open angle glaucoma. Eye 8, 410–413 (1994).
10. Zimmerman TJ, Sharir M, Nardin GF, Fuqua M. Therapeutic index of pilocarpine, carbachol, and timolol with nasolacrimal occlusion. Am. J. Ophthalmol. 114, 1–7 (1992).
11. Bron AJ, Chidlow G, Melena J, Osborne NN. β-blocker in the treatment of glaucoma. In: Pharmacotherapy in Glaucoma. Orgul S, Flammer J (Eds). Verlag Hans Huber, WA, USA, 79–113 (2000).
12. McCue BA, Cason MM, Curtis MA, Faulkner RD, Dahlin DC. Determination of travoprost and travoprost free acid in human plasma by electrospray HPLC/MS/MS. J. Pharm. Biomed. Anal. 28, 199–208 (2002).
13. Waugh J, Jarvis B. Travoprost. Drugs Aging 19, 465–471 (2002).
14. Al-Jazzaf AM, DeSantis L, Netland PA. Travoprost: a potent ocular hypotensive agent. Drugs Today (Barc.) 39, 61–74 (2003).
15. Ota T, Aihara M, Narumiya S, Araie M. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest. Ophthalmol. Vis. Sci. 46, 4159–63 (2005).
16. Toris CB, Zhan GL, Camras CB, McLaughlin MA. Effects of travoprost on aqueous humor dynamics in monkeys. J. Glaucoma 14, 70–73 (2005).
17. Barnebey H, Orengo-Nania S, Flowers BE et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am. J. Ophthalmol. 140, 1–7 (2005).
18. Hughes BA, Bacharach J, Craven ER et al. A three-month, multicenter, double-masked, study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open-angle glaucoma or ocular hypertension. J. Glaucoma 14, 392 –399 (2005).
19. Schuman JS, Katz GJ, Lewis RA et al. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. 140, 242–250 (2005).
20. Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am. J. Ophthalmol. 135, 688–703 (2003).
21. Netland PA, Landry T, Sullivan EK et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. 132, 472–484 (2001).
22. DuBiner HB, Sircy MD, Landry T et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin. Ther. 26, 84–91 (2004).
23. Zimmerman TJ, Kass MA, Yablonski ME, Becker B. Timolol maleate: efficacy and safety. Arch. Ophthalmol. 97, 656–658 (1979).
24. Boger WP III, Steinert RF, Thomas JV. Timolol in the therapy of ‘ocular hypertension’. Surv. Ophthalmol. 25, 195–202 (1980).
25. Danesh-Mayer H, Wells A, Wieland H for the Trav/Tim 1-year study group. A one-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open angle glaucoma or ocular hypertension. Poster presented at: the Asian Oceanic Glaucoma Society, North Queensland, Australia, September 1–3, 2005.